Adverse events | Grade | Cases (incidence rate %) |
---|---|---|
Leukopenia | Grade 1–2 | 27 (38.03%) |
Grade 3–4 | 19 (26.76%) | |
Neutropenia | Grade 1–2 | 23 (32.39%) |
Grade 3–4 | 12 (16.90%) | |
Thrombocytopenia | Grade 1–2 | 17 (23.94%) |
Grade 3–4 | 7 (9.86%) | |
Anemia | Grade 1–2 | 31 (43.66%) |
Grade 3–4 | 12 (16.90%) | |
Nausea | Grade 1–2 | 20 (28.17%) |
Grade 3–4 | 3 (4.23%) | |
Vomiting | Grade 1–2 | 18 (25.35%) |
Grade 3–4 | 2 (2.82%) | |
Diarrhea | Grade 1–2 | 7 (9.86%) |
Grade 3–4 | 2 (2.82%) | |
Neurotoxicity | Grade 1–2 | 4 (5.63%) |
Grade 3–4 | 1 (1.41%) | |
Transaminase elevation | Grade 1–2 | 13 (18.31%) |
Grade 3–4 | 2 (2.82%) | |
Renal toxicity | Grade 1–2 | 9 (12.67%) |
Grade 3–4 | 3 (4.23%) | |
Weakness | Grade 1–2 | 33 (46.47%) |
Grade 3–4 | 5 (7.04%) | |
Rash | Grade 1–2 | 9 (12.67%) |
Grade 3–4 | 3 (4.23%) | |
Myalgia | Grade 1–2 | 3 (4.23%) |
Arrhythmia | Grade 1–2 | 2 (2.82%) |